PureTech's Gallop Oncology Reports 13.2-Month Survival with LYT-200 in AML Phase 1b Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 05 2025
0mins
Source: Businesswire
- Clinical Trial Results: Gallop Oncology's Phase 1b trial of LYT-200 in relapsed/refractory acute myeloid leukemia (AML) patients demonstrated a favorable tolerability and strong efficacy, with initial median overall survival data of 13.2 months, indicating a potential breakthrough in treatment options.
- Patient Transition Rates: Among patients treated with LYT-200 in combination with standard care, 33% achieved complete response, and 50% of these patients proceeded to stem cell transplant, showcasing the drug's broad applicability in high-risk mutation populations.
- Safety Analysis: The trial reported no serious adverse events related to LYT-200, and no additive toxicities were observed when combined with standard treatments, indicating a favorable safety profile that could provide better treatment options for patients.
- Future Development Plans: Gallop Oncology intends to engage with regulatory authorities in the first half of 2026 to discuss the registrational path for the Phase 2 trial, with LYT-200 having received Fast Track and Orphan Drug designations from the FDA, highlighting its significant potential in AML treatment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PRTC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PRTC
About PRTC
PureTech Health plc is a clinical-stage company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company is engaged in the development of around 29 therapeutics and therapeutic candidates, including three that have been approved by the United States Food and Drug Administration. A number of these programs are advanced by the Company or its Founded Entities in various indications and stages of clinical development. Its primary programs include LYT-100 and LYT-200. Deupirfenidone (LYT-100) is being developed as a potential new standard of care (SOC) for the treatment of idiopathic pulmonary fibrosis (IPF). LYT-200 is an anti-galectin-9 monoclonal antibody (mAb) being developed for the treatment of hematological malignancies, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS), as well as solid tumors, including head and neck cancers, with a focus on metastatic disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Robert Lyne Appointed CEO of PureTech
- New CEO Appointment: PureTech Health has appointed Robert Lyne as the new chief executive officer.
- Announcement Date: The announcement regarding the appointment was made on Thursday.
Continue Reading
PureTech Appoints Robert Lyne as CEO, Focuses on Funding and Innovation
- Leadership Change: PureTech Health plc appoints Robert Lyne as CEO, aiming to leverage his extensive experience in the biotech sector to drive the company's strategic development in innovation and funding.
- Funding Plans: The company plans to secure funding for its newly founded entity, Celea Therapeutics, by the first half of 2026, which is expected to significantly reduce operational costs and enhance shareholder value.
- Capital Efficiency Improvement: Lyne emphasizes a streamlined operational structure and a disciplined investment strategy to ensure efficient capital utilization while advancing key innovation initiatives.
- Strategic Focus: The new CEO will concentrate on optimizing shareholder returns, with plans to evaluate potential capital return methods after Celea is fully financed, ensuring sustained growth in the biopharmaceutical sector.
Continue Reading